FERROUS GLUCONATE Coated tablet (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Ferrous Gluconate 300mg Tablets.
Qualitative and quantitative composition
Each tablet contains 300mg ferrous gluconate. Excipients with known effect: contains sucrose and ponceau 4R red (E124). For a full list of excipients, see section 6.1.
Pharmaceutical form
Coated tablet. Appearance: Red, circular, biconvex, sugar-coated tablet.
Therapeutic indications
Ferrous Gluconate 300mg Tablets are indicated for the prevention and treatment of iron deficiency states.
Posology and method of administration
Adults and the elderly <u>Prophylactic:</u> 2 tablets daily. <u>Therapeutic:</u> 4-6 tablets daily in divided doses. Children (aged 6-12 years) <u>Prophylactic:</u> 1 or 2 tablets daily. <u>Therapeutic: ...
Contraindications
Hypersensitivity to the active ingredient ferrous gluconate or to any of the excipients listed in section 6.1. Iron preparations are contra-indicated in patients with haemochromatosis, iron storage or ...
Special warnings and precautions for use
Large doses may have irritant/corrosive effect on gastro-intestinal mucosa which can lead to necrosis and perforation. Ferrous Gluconate should be used with caution in patients with haemolytic anaemia. ...
Interaction with other medicinal products and other forms of interaction
Iron and possibly other heavy metals are chelated with concurrent oral administration of acetohydroxamic acid resulting in reduced intestinal absorption of both drugs. <u>Antacids and mineral supplements: ...
Pregnancy and lactation
Use of any drug during the first trimester of pregnancy should be avoided if possible. Thus administration of iron during the first trimester requires definite evidence of iron deficiency. There is no ...
Effects on ability to drive and use machines
None known.
Undesirable effects
Gastro-intestinal disorders have been reported with large doses of Iron including gastro-intestinal discomfort, epigastric pain, anorexia, nausea, heartburn, vomiting, constipation, and diarrhoea. These ...
Overdose
Large amounts of Ferrous gluconate are toxic, but in adults rarely prove fatal. In children between 1 and 2 years of age as little as 1 to 2 g of iron can cause death. Symptoms Iron poisoning is commonest ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antianemic preparations ATC code: B03AA03 Iron is an essential constituent of the body, being necessary for haemoglobin formation and for the oxidative processes of living tissues. ...
Pharmacokinetic properties
After acidification and partial digestion of food in the stomach its content of iron is presented to the intestinal mucosa as either inorganic or heme iron. These fractions are taken up by the absorptive ...
Preclinical safety data
Not available.
List of excipients
Sodium starch glycollate Stearic acid Colloidal anhydrous silica <u>Sugar-coat excipients:</u> Sucrose Polyvinylacetate phthalate Stearic acid Talc Calcium carbonate Acacia Titanium dioxide(E171) Ponceau ...
Incompatibilities
None known.
Shelf life
3 years.
Special precautions for storage
Do not store above 25°C. Keep the container tightly closed. Store in theoriginal container.
Nature and contents of container
Polypropylene tubes with high-density/low-density polyethylene caps and a silica gel desiccant. A low-density polyethylene bag contains the leaflet in the pot. Pack sizes: 28, 100, 250,500, 1000 and 5000 ...
Special precautions for disposal and other handling
Not applicable.
Marketing authorization holder
Athlone Pharmaceuticals Limited, Ballymurray, Co. Roscommon, Ireland
Marketing authorization number(s)
PL 30464/0026
Date of first authorization / renewal of the authorization
Date of first authorisation: 07/08/1979 Date of last renewal: 21/09/2006
Date of revision of the text
18 June 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
